Novo upon billion-dollar bid: An acquisition of Ablynx will not satisfy our hunger

Novo Nordisk is currently offering billions in the attempt to acquire the Belgian biotech company Ablynx. And according to Christian Kanstrup, SVP Biopharm operations, the Danish corporation is not planning to cease its acquisitions afterwards.

Photo: Novo Nordisk/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Related articles